RERE-AS1 enhances the effect of CDK4/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway
The ANNM established through ML algorithms can serve as predictive indicators for the efficacy of ribociclib in BC patients. LncRNA RERE-AS1, a newly discovered biomarker, holds significant promise for diagnosis, treatment, and enhancing the therapeutic response to ribociclib in BC.
Authors
- Debo Chen (ORCID: https://orcid.org/0000-0003-3524-063X)
- Kaixin Lou
- Zhidong Huang (ORCID: https://orcid.org/0000-0002-5267-5769)
- Chen Wang (ORCID: https://orcid.org/0000-0002-9974-8590)
- Jinhui Wang
- Hong Liu
- Linwei Li (ORCID: https://orcid.org/0000-0002-8406-8322)
- Mengyang Qi
- Xirui Zhou (ORCID: https://orcid.org/0000-0002-4838-6729)
- Bo Sun
Institutions
- Fujian Medical University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2024-11-22
- DOI
- https://doi.org/10.1186/s12967-024-05828-x
- Citations
- 3
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Tianjin Medical University
- Wu Jieping Medical Foundation